

**REF** BIO64RT  
96 well  
plate



**ARGUTUS MEDICAL**  
An EKF Diagnostics Company

# Rat Alpha GST EIA

**Enzyme Immunoassay**

**Instructions for Use**

**FOR RESEARCH USE ONLY**  
**Not for use in Diagnostic Procedures**

**TABLE OF CONTENTS**

INTENDED USE	3
BACKGROUND	3
ASSAY PRINCIPLE	3
COMPONENTS	4
PRECAUTIONS	5
STABILITY AND STORAGE	6
ADDITIONAL MATERIALS REQUIRED	6
PREPARATION OF REAGENTS	7
SAMPLE COLLECTION, HANDLING AND STORAGE	8
SAMPLE PREPARATION	8
ASSAY PROCEDURE	9
CALCULATION OF RESULTS	10
EXAMPLE OF CALIBRATION CURVE	10
PERFORMANCE CHARACTERISTICS	11
APPENDIX 1	13
WARRANTY	13
SUMMARY OF ASSAY PROCEDURE	14
REFERENCES	15
OTHER ARGUTUS MEDICAL ASSAYS	16

## **INTENDED USE**

Argutus Medical Rat Alpha GST EIA is an enzyme immunoassay for the quantitative estimation of rat alpha Glutathione S-Transferase ( $\alpha$ GST) in biological fluids such as serum, urine and tissue culture supernatants.

## **BACKGROUND**

### **HEPATIC STUDIES**

$\alpha$ GST is a highly sensitive and specific biomarker of hepatocyte injury. The protein is found throughout the liver parenchyma in high concentrations<sup>1, 2</sup>. In the event of liver injury,  $\alpha$ GST is released more rapidly than transaminases and has a shorter half-life in the circulation. Therefore,  $\alpha$ GST levels more accurately indicate the onset and resolution of hepatocyte injury than transaminases<sup>3, 4</sup>.  $\alpha$ GST has been proven to be a superior indicator of hepatocyte injury in hepatotoxicity<sup>3-5</sup>, transplantation<sup>6, 7</sup> and ischemia-reperfusion injury<sup>8</sup>.  $\alpha$ GST is a valuable marker for studying the use of extracorporeal support devices<sup>9</sup>, where the use of the Argutus Medical rat  $\alpha$ GST EIA kit enables the status of the host liver and experimental support device to be studied separately<sup>9</sup>.

### **RENAL STUDIES**

In the rat kidney,  $\alpha$ GST is found in the proximal convoluted tubules<sup>10</sup>. It is readily and rapidly released into the urine when renal tubular injury occurs<sup>11-13</sup>. Urinary  $\alpha$ GST levels correlate closely with the time course<sup>11</sup> and the severity of renal injury<sup>12</sup>. Urinary  $\alpha$ GST levels are more sensitive indicators of renal tubular injury than serum creatinine<sup>12</sup>.

## **ASSAY PRINCIPLE**

The Argutus Medical Rat Alpha GST EIA is a quantitative solid phase enzyme immunoassay. The test procedure is based on the sequential addition of sample, antibody-enzyme conjugate and substrate to microassay wells coated with anti-rat  $\alpha$ GST IgG. The resultant colour intensity is proportional to the amount of  $\alpha$ GST in the sample. The assay range is 1.56-100 $\mu$ g/L.

## COMPONENTS

Each Argutus Medical Rat Alpha GST EIA contains reagents for 96 assay wells, sufficient for 39 samples in duplicate.

- |  |   |         |      |     |
|--|---|---------|------|-----|
| <p>1. Antibody coated Microassay plate<br/>96 wells (12x8 breakapart well strips) coated with IgG directed against rat <math>\alpha</math>GST.<br/>READY TO USE</p>  | <table border="1" style="border-collapse: collapse; width: 60px; height: 25px;"> <tr> <td style="text-align: center; padding: 2px;">PLA</td> </tr> </table>   | PLA     |      |     |
| PLA  |   |         |      |     |
| <p>2. Enzyme Conjugate, 11mL<br/>Solution containing anti-rat <math>\alpha</math>GST IgG conjugated to horseradish peroxidase with ProClin950 and Bronidox L as preservatives.<br/>READY TO USE</p>  | <table border="1" style="border-collapse: collapse; width: 60px; height: 25px;"> <tr> <td style="text-align: center; padding: 2px;">CONJ</td> </tr> </table>  | CONJ    |      |     |
| CONJ   |   |         |      |     |
| <p>3. <math>\alpha</math>GST Calibrator, 0.1mL (5.1mg/L)<br/>Purified rat <math>\alpha</math>GST (YaYc isoform) in stabilising diluent containing ProClin950 and Bronidox L as preservatives<br/><b>Store at -20°C until required</b><br/>51X STOCK SOLUTION</p> | <table border="1" style="border-collapse: collapse; width: 60px; height: 25px;"> <tr> <td style="text-align: center; padding: 2px;">CAL</td> </tr> </table>   | CAL     |      |     |
| CAL  |   |         |      |     |
| <p>4. Positive Control, 0.15mL<br/>Purified rat <math>\alpha</math>GST in stabilising diluent containing ProClin950 and Bronidox L as preservatives<br/><b>Store at -20°C until required</b><br/>50X STOCK SOLUTION</p>  | <table border="1" style="border-collapse: collapse; width: 100px; height: 25px;"> <tr> <td style="text-align: center; padding: 2px;">CONTROL</td> <td style="text-align: center; padding: 2px;">+</td> </tr> </table>   | CONTROL | +    |     |
| CONTROL  | +   |         |      |     |
| <p>5. Rat Urinary Stabilising Buffer, 10mL<br/>Contains ProClin950 and Bronidox L as preservatives<br/>READY TO USE</p>  | <table border="1" style="border-collapse: collapse; width: 100px; height: 25px;"> <tr> <td style="text-align: center; padding: 2px;">BUF</td> <td style="text-align: center; padding: 2px;">NEPH</td> </tr> </table>  | BUF     | NEPH |     |
| BUF  | NEPH  |         |      |     |
| <p>6. Sample Diluent, 55mL<br/>Protein containing solution with added stabilisers containing ProClin 950 and Bronidox L as preservatives<br/>READY TO USE</p>  | <table border="1" style="border-collapse: collapse; width: 100px; height: 25px;"> <tr> <td style="text-align: center; padding: 2px;">DIL</td> <td style="text-align: center; padding: 2px;">SPE</td> <td style="text-align: center; padding: 2px;">1X</td> </tr> </table>   | DIL     | SPE  | 1X  |
| DIL  | SPE   | 1X      |      |     |
| <p>7. Wash Buffer, 55mL<br/>Tris-buffered saline / Tween-20 (TBST) containing ProClin 950 as preservative.<br/>25X CONCENTRATE</p>   | <table border="1" style="border-collapse: collapse; width: 100px; height: 25px;"> <tr> <td style="text-align: center; padding: 2px;">BUF</td> <td style="text-align: center; padding: 2px;">WASH</td> <td style="text-align: center; padding: 2px;">25X</td> </tr> </table> | BUF     | WASH | 25X |
| BUF  | WASH  | 25X     |      |     |
| <p>8. Substrate, 11mL<br/>Stabilised liquid TMB solution (11mL).<br/>READY TO USE</p>  | <table border="1" style="border-collapse: collapse; width: 100px; height: 25px;"> <tr> <td style="text-align: center; padding: 2px;">SUBS</td> <td style="text-align: center; padding: 2px;">TMB</td> </tr> </table>  | SUBS    | TMB  |     |
| SUBS   | TMB   |         |      |     |
| <p>9. Stop Solution, 11mL<br/>0.5M Sulphuric Acid.<br/>READY TO USE</p>  | <table border="1" style="border-collapse: collapse; width: 100px; height: 25px;"> <tr> <td style="text-align: center; padding: 2px;">SOLN</td> <td style="text-align: center; padding: 2px;">STP</td> </tr> </table>  | SOLN    | STP  |     |
| SOLN   | STP   |         |      |     |
| <p>10. Instructions for use</p>  | <table border="1" style="border-collapse: collapse; width: 60px; height: 25px;"> <tr> <td style="text-align: center; padding: 2px;">INS</td> </tr> </table>   | INS     |      |     |
| INS  |   |         |      |     |

## **PRECAUTIONS**

### **SAFETY**

- The Argutus Medical Rat Alpha GST EIA kit is for research use only and is not for use in diagnostic procedures.
- The Argutus Medical Rat Alpha GST EIA kit is intended for use by qualified laboratory staff only.
- The Stop Solution contains sulphuric acid, which is corrosive and causes burns. Avoid contact with the skin and eyes. If contact occurs, rinse off immediately with water and seek medical advice.
- The Substrate contains TMB, which may irritate the skin and mucous membranes. Any substrate, which comes in contact with the skin, should be rinsed off with water.
- Dispose of all infected or potentially infected material in accordance with good laboratory practice. All such materials should be treated as potentially infectious.
- Residues of chemicals and kit components are generally considered as hazardous waste. All such materials should be disposed of in accordance with established safety procedures.
- Wear protective clothing, disposable latex gloves and eye protection while handling specimens and performing the assay. Wash hands thoroughly when finished.
- Do not pipette materials by the mouth and never eat or drink at the laboratory workbench.
- The components containing ProClin 950 are classified as per applicable European Community (EC) directives as: Irritant (Xi). The following are appropriate Risk (R) and Safety (S) phrases:
  - R43 May cause sensitization by skin contact.
  - S24 Avoid contact with skin.
  - S35 This material and its container must be disposed of in a safe way.
  - S37 Wear suitable gloves.
  - S46 If swallowed, seek medical advice immediately and show this container or label.

### **PROCEDURAL**

- Do not use kit, or individual reagents, which are past their expiry date.
- Do not mix or substitute reagents from kits with different lot numbers.
- Deviation from the protocol provided may cause erroneous results.
- Performing the assay outside the time and temperature ranges specified may produce invalid results. Assays that do not fall within the established time and temperature ranges must be repeated.
- Reagent delivery should be aimed at midpoint of the side of the wells, taking care not to touch the sides of the wells with the pipette tip.
- Do not allow the wells to dry at any stage during the assay procedure.
- Care must be taken not to contaminate components and always use fresh pipette tips for each sample and component.
- Do not use reagents that contain precipitates or that are cloudy in appearance.
- High quality distilled or deionised water is required for the Wash Solution. The use of poor quality or contaminated water may lead to background colour in the assay.
- Allow all reagents to come to room temperature (20-25°C) and mix well prior to use.
- Avoid leaving reagents in direct sunlight and/or above 2-8°C for extended periods.
- Always use clean, preferably disposable, glassware for all reagent preparation.
- Ensure that the bottom surface of the plate is clean and dry before reading.
- Before commencing the assay, an identification and distribution plan should be established.

- Always keep the upper surface of the wells free of droplets. Drops should be gently blotted dry on completion of the procedural step if required.

### **STABILITY AND STORAGE**

1. All kit reagents should be stored at 2-8°C **except for the  $\alpha$ GST Calibrator and Positive Control stock solutions which should be stored at -20°C on delivery.** All reagents are stable as supplied until the expiry date shown. The  $\alpha$ GST Calibrator and Positive Control stock solutions are stable for 1 week at 2-8°C.
2.  $\alpha$ GST Calibrators and diluted Positive Control must be used within 1 hour of preparation.
3. Once diluted, the Wash Solution can be stored at 18-25°C for two weeks or 2-8°C for one month.
4. Microassay wells should be stored in sealed foil pouches with desiccants at 2-8°C until required for use. Return unused wells to storage pouch together with desiccant.

### **ADDITIONAL MATERIALS REQUIRED**

1. Micropipettes and a multichannel pipette
2. Microassay strip washing system
3. ELISA plate reader capable of measuring at 450nm with reference at 630nm if available
4. Timer
5. Liquid trough
6. Graduated cylinder
7. Test tubes
8. Deionised/Distilled water
9. Plate ShakerRoom temperature incubator
10. Vortex

## **PREPARATION OF REAGENTS**

**Note:** All reagents should be allowed to reach room temperature prior to commencement of assay. Components from different batches of Argutus Medical Rat Alpha GST EIA kits must not be intermixed.

### **WASH SOLUTION**

Prepare a 1/25 dilution of Wash Concentrate adding, for example, 10mL Wash Concentrate to 240mL deionised water as required. Prepare only the volume of Wash Solution required for the assay. Each strip of 8 microassay wells requires 35mL of Wash Solution.

### **CALIBRATORS**

Dilute the rat  $\alpha$ GST calibrator stock solution (5.1mg/L) as follows:

Stock:	20 $\mu$ L
Sample Diluent:	<u>1000<math>\mu</math>L</u>
Total:	1020 $\mu$ L @ 100 $\mu$ g/L (A)

Mix Calibrator (A) by vortexing for 5 – 10 seconds. Using labelled test tubes, prepare further calibrators as follows:

<b>Rat <math>\alpha</math>GST Calibrator Concentration (<math>\mu</math>g/L)</b>	<b>Calibrator Volume (<math>\mu</math>L)</b>	<b>Sample Diluent Volume (<math>\mu</math>L)</b>
100 (A)	500 (A)	0
50.0 (B)	500 (A)	500
25.0 (C)	500 (B)	500
12.5 (D)	500 (C)	500
6.25 (E)	500 (D)	500
3.12 (F)	500 (E)	500
1.56 (G)	500 (F)	500
0 (H)	0	500

### **POSITIVE CONTROL**

Dilute Positive Control 1/50 in Sample Diluent; i.e. add 10 $\mu$ L Positive Control to 490 $\mu$ L Sample Diluent. Mix diluted Positive Control by vortexing for 5 – 10 seconds.

## **SAMPLE COLLECTION, HANDLING AND STORAGE**

### **SERUM**

For serum sample analysis, blood samples should be allowed to clot at room temperature for 2 hours or 2-8°C overnight. The sample is then centrifuged (3000 rpm/10 minutes) and the serum collected.

Serum samples should be assayed immediately or may be stored at 2-8°C for 4 days. If necessary, the samples may be frozen at -20°C. Avoid repeated freezing and thawing. Do not store diluted samples. Samples can be stored at -20°C for at least one month.

### **URINE**

As soon as possible after sample collection, add 100µL of Rat Urine Stabilising Buffer to 400µL urine (4/5 dilution of sample), even if the samples are not to be stored.

Do not store samples without the addition of Rat Urine Stabilising Buffer. Rat Urine Stabilising Buffer should be added within 12 hours of sample collection.

After the addition of Rat Urine Stabilising Buffer, samples can be stored at 2-8°C for at least 48 hours or at -20°C for at least a month.

### **TISSUE CULTURE SUPERNATANT**

A hepatocyte cell number of  $4 \times 10^5$  cells /mL cell culture medium is recommended.

## **SAMPLE PREPARATION**

### **SERUM**

Dilute serum samples 1/50 in Sample Diluent i.e. add 10µL serum sample to 490µL Sample Diluent. Samples expected to contain levels above 2500µg/L should be diluted further.

### **URINE**

Dilute urine samples 1/5 in Sample Diluent i.e. add 100µL urine sample to 400µL sample diluent. Samples expected to contain levels above 250µg/L should be diluted further.

### **TISSUE CULTURE SUPERNATANT**

Samples should be diluted 1/5 to 1/30 in Sample Diluent depending on expected concentrations. These dilution factors may vary for the cell culture system used.

**Do not store diluted samples of any kind.**

## **ASSAY PROCEDURE**

To obtain precise reproducible results, it is essential that care be taken during reagent addition to the microassay wells and with the washing steps. The following points should be noted:

- Do not touch the sides of the microassay wells with pipette tips during reagent addition.
- During the washing steps, fill wells evenly and aspirate completely.
- At the end of the last wash step, remove any remaining drops by tapping the microassay plate hard against paper towels until no more drops are remaining. Do not dry the inside of the wells.
- Add next reagent promptly.

### **1. SAMPLE/CALIBRATOR INCUBATION**

- 1.1. Prepare Wash Solution, Positive Control and Calibrators as described in “Preparation of reagents”.
- 1.2. Prepare samples as outlined in “Sample Preparation”.
- 1.3. Place required number of microassay wells in the assay plate (16 for the Calibrators, two for the Positive Control plus two per sample). Add Calibrators (H-A; equivalent concentration 0-100µg/L), Positive control and diluted samples (100µL/well), in duplicate, to the microassay plate.
- 1.4. Cover the microassay plate and incubate at room temperature (20-25°C) for 60 ± 2 minutes with uniform shaking (350 ± 10rpm).
- 1.5. Remove cover and wash each strip 6 times with Wash Solution (250-350µL/well). When complete, firmly tap the plate against a paper towel to ensure complete removal of wash fluid from wells.

**Note:** Either automated or manual washing is acceptable.

### **2. CONJUGATE INCUBATION**

- 2.1. Add **100µL** conjugate/well to the microassay plate using a multichannel pipette, taking care not to touch the sides of the microassay wells with the pipette tips.
- 2.2. Again cover the microassay plate and incubate at room temperature (20-25°C) for **60 ± 2 minutes** with uniform shaking (350 ± 10rpm).
- 2.3. Wash each strip as in step 1.5 above.

### **3. COLOUR DEVELOPMENT**

- 3.1. Add **100µL** Substrate/well using a multichannel pipette and incubate at room temperature in the dark for 15 minutes exactly with NO shaking. Again, take care not to touch the sides of the microassay wells with the pipette tips.


### **4. STOP**

- 4.1. Stop the reaction by addition of **100µL** Stop Solution/well. Ensure complete mixing of Substrate and Stop Solution.
- 4.2. Read immediately 450nm with 630nm as reference if available.

## **CALCULATION OF RESULTS**

1. Calculate the mean absorbance for each Calibrator, the Positive Control and samples.
2. Plot a calibration curve of  $A_{450/630nm}$  versus  $[\alpha\text{GST}]\text{-}\mu\text{g/L}$  (4-parameter plot, refer to Figure 1).
3. Read the  $\alpha\text{GST}$  concentration ( $\mu\text{g/L}$ ) indicated by the mean absorbance of the Positive Control or sample from the calibration curve
4. The concentration of the Positive Control is read directly from the curve. Its value should be within the range given on the inside of the box lid.
5. Multiply the  $\alpha\text{GST}$  concentration obtained for samples by the appropriate dilution factor.
6. Results for urine samples to which Argutus Medical Rat Urine Stabilising Buffer has been added should be multiplied by a factor of 1.25 to allow for 4/5 dilution of the sample.
7. Concentrations of samples with readings outside the standard curve are invalid and must be repeated with a higher dilution factor. It is not acceptable to extrapolate data.
8. Please see Appendix 1 for instructions on how to express urinary  $\alpha\text{GST}$  as rate (ng/min).

## **EXAMPLE OF A CALIBRATION CURVE**



**Figure 1:** Typical calibration curve obtained using Argutus Medical Rat Alpha GST EIA. 4-parameter plot of  $A_{450/630nm}$  versus  $[\alpha\text{GST}]\ \mu\text{g/L}$ . Assay range is 1.56 – 100 $\mu\text{g/L}$   $\alpha\text{GST}$ .

## **PERFORMANCE CHARACTERISTICS**

### **REFERENCE RANGES**

#### **SERUM**

Sprague-Dawley Rats 43 ± 56µg/L (mean ± 2SD)

#### **URINE**

Sprague-Dawley Rats 46.9 ± 44.6µg/L (mean ± 2SD)

Wistar Rats 23.0 ± 26.4µg/L (mean ± 2SD)

Normal ranges may vary between different rat strains. Therefore, it is important for each laboratory to assess a normal range for the rat strain used in the study. Contact Argutus Medical for advice.

### **MEASURING RANGE**

The calibration range covers 1.56-100 µg/L corresponding to 7.8 to 5000µg/L using 1/50 dilution (serum) or 9.75 to 625 µg/L in stabilised urine samples diluted 1/5. This range may be extended by increasing sample dilution.

### **REPRODUCIBILITY**

**Table 1.** Inter-assay Variation of the Argutus Medical Rat Alpha GST EIA

<b>Sample</b>	<b>Mean Final Conc. αGST µg/L</b>	<b>% CV</b>	<b>n</b>
Low Urine	45	8.8	11
High Urine	247	12.0	11
Low Serum	1545	10.9	11
High Serum	3472	13.5	11

### **LIMIT OF DETECTION**

The detection limit of Argutus Medical Rat Alpha GST EIA is 0.2µg/L in the microassay well, equivalent to 10µg/L in a serum sample diluted to 1/50, or 1.25µg/L in a stabilised urine sample, diluted 1/5.

### **SPECIFICITY**

The Argutus Medical Rat Alpha GST EIA is highly specific for rat αGST (YaYc isoforms). No significant cross-reactivity is observed with Yp or Yb1 isoforms. Cross reactivity with human, canine and porcine αGST is undetectable.

**LINEARITY**

**Table 2.** Linearity testing using Argutus Medical Rat Alpha GST EIA

Sample	Test Dilution	Expected Final Conc. $\alpha$ GST $\mu$ g/L	Measured Final Conc. $\alpha$ GST $\mu$ g/L	% Recovery
Low Urine	5	N/A	44	N/A
	10	44	42	95%
	20	44	40	91%
	40	44	44	100%
High Urine	5	N/A	220	N/A
	10	220	205	93%
	20	220	210	96%
	40	220	252	115%
Low Serum	25	N/A	1520	N/A
	50	1520	1445	95%
	100	1520	1390	91%
	200	1520	1500	99%
High Serum	50	N/A	3035	N/A
	100	3035	2940	97%
	200	3035	2400	79%
	400	3035	2600	86%

**SPIKE RECOVERY**

**Table 3.** Spike Recovery testing using Argutus Medical Rat Alpha GST EIA

Sample	$\alpha$ GST Spike Level	Measured Final Conc. $\alpha$ GST $\mu$ g/L	Expected Final Conc. $\alpha$ GST $\mu$ g/L	% Recovery
Low Urine	Low	152	154	99%
	High	536	574	93%
High Urine	Low	298	278	107%
	High	722	698	103%
Low Serum	Low	1455	1627	89%
	High	2100	2047	103%
High Serum	Low	2660	3002	89%
	High	3250	3422	95%

## **APPENDIX 1**

### **EXPRESSING THE RELEASE OF $\alpha$ GST IN TERMS OF RATE**

In situation of unusual diuresis, e.g., poly- or oligouria, it may be more relevant to express  $\alpha$ GST release in terms of rate ( $\alpha$ GST ng/min) rather than concentration. The rate of release is obtained as follows:

### **URINE COLLECTION**

Collect urine samples as described in "Sample Collection and Handling".  
Note the period of urine collection (T) in minutes and total urine volume (V).

### **CALCULATION OF $\alpha$ GST RELEASE RATE**

1. Determine urinary  $\alpha$ GST levels using the Argutus Medical Rat Alpha GST EIA ( $\mu$ g/L).
2. Note the period over which the urine was collected (T) in minutes.
3. Note the urine volume in mL (V).
4. Calculate the excretion rate as follows:

$$\alpha\text{GST (ng/min)} = \frac{([\alpha\text{GST}] \mu\text{g/L}) \times V}{T}$$

## **WARRANTY**

The performance data presented here was obtained using the procedure described. Any change or modification of the procedure, not recommended by Argutus Medical, may affect the results, in which case Argutus Medical disclaims all warranties, expressed, implied or statutory, including implied merchantability and fitness for use. In the case of such an event, Argutus Medical shall not be liable for damages, direct or consequential.

## **SUMMARY OF ASSAY PROCEDURE**

**Note: all incubations are performed at room temperature**

1. Pipette: 100µL standards/positive control/sample

 Incubate: 60 min

 Wash: 6 X 300µL

2. Pipette: 100µL enzyme conjugate

 Incubate: 60 min

 Wash: 6 X 300µL

3. Pipette: 100µL substrate

 Incubate: 15 min

4. Pipette: 100µL stop solution

 Read immediately: 450nm/630nm

## **REFERENCES**

1. **Redick, J.A. et al.** (1982). Immunological localisation of glutathione S-transferases in livers of untreated rats. *Journal of Biological Chemistry* **257(24)**, 15200-15203.
2. **Bass, N.M. et al.** (1977). Radioimmunoassay of ligandin. *Biochimica et Biophysica Acta* **494**, 131-143.
3. **Bass, N.M. et al.** (1978). Radioimmunoassay of plasma ligandin – A sensitive index of experimental hepatocellular necrosis. *Gastroenterology* **75**, 589-594
4. **Clarke, H. et al.** (1997) Glutathione S-transferase ( $\alpha$ GST) release, an early indicator of carbon tetrachloride hepatotoxicity in the rat. *Human and Experimental Toxicology* **16**, 154-157.
5. **Battiston, L. et al.** (1996) Alcohol hepatic toxicity in the rat: evidence of the utility of gastric alcohol metabolism. *International Hepatology Communications* **6**, 61-70.
6. **Egawa, H. et al.** (1995) Acute liver allograft rejection in the rat. *Transplantation* **59**, 97-102.
7. **Krams, S.M. et al.** (1995) Apoptosis as a mechanism of cell death in liver allograft rejection. *Transplantation*, **59**, 621-625.
8. **Van Wagensveld, B.A. et al.** (1997). Alpha glutathione S-transferase as a novel parameter for hepatocellular damage in isolated perfused rat liver. *Transplantation Proceedings* **29**, 3449-3451.
9. **Flendrig, L.M. et al.** (1999) Evaluation of a novel bioartificial liver in rats with complete liver ischemia: treatment efficacy and species specific  $\alpha$ GST detection to monitor hepatocyte viability. *Journal of Hepatology* **30**, 311-320.
10. **Rozell, B. et al.** (1993). Glutathione transferases of classes alpha, mu and pi show selective expression in different regions of rat kidney. *Xenobiotica*. **23(8)**: 835-49.
11. **Bass, N.M. et al.** (1979) Radioimmunoassay measurement of urinary ligandin excretion in nephrotoxin treated rats.
12. **Kharasch, E.D. et al.** (1998). Role of renal cysteine conjugate  $\beta$ -lyase pathway in inhaled compound a nephrotoxicity in rats. *Anesthesiology* **88(6)**, 1624-1633.
13. **Usuda, K et al.** (1998) Urinary biomarkers monitoring for experimental fluoride toxicity. *Archives of Toxicology* **72**, 104-109.

## **OTHER ARGUTUS MEDICAL ASSAYS**

### **PRODUCTS FOR DETECTING HUMAN ORGAN DAMAGE**

<b>Catalogue No.</b>	<b>Product Description</b>	<b>Assay Format</b>
H-RENA-E-001	Urinary KIM-1 EIA	96 Well EIA
H-RENA-E-005	Urinary KIM-1 EIA	5 x 96 Well EIA
H-RENA-25	Urinary KIM-1 Rapid Test	25 strips
H-RENA-50	Urinary KIM-1 Rapid Test	50 strips
Z-001	Urinary L-FABP EIA	96 Well EIA
BIO83	Urinary Collagen IV EIA	96 Well EIA
BIO85STB	Urine Stabilising Buffer	10 mL
BIO85STBC	Custom Filled Urine Stabilising Buffer Tubes	1 mL
BIO82	Serum Collagen IV EIA	96 Well EIA
BIO85	Human Pi GST EIA	96 Well EIA
BIO90NGAL	Human NGAL EIA	2 x 96 Well EIA
BIO91	Human Alpha GST EIA	96 Well EIA
BIO81DNA	OxyDNA Test	50 Determinations
BIO84	Collagen IV Urine Collecting Tubes	

### **PRODUCTS FOR DETECTING RAT ORGAN DAMAGE**

<b>Catalogue No.</b>	<b>Product Description</b>	<b>Assay Format</b>
R-RENA-E-001	Rat Urinary KIM-1 EIA	96 Well EIA
R-RENA-E-005	Rat Urinary KIM-1 EIA	480 Well EIA
R-RENA-25	Rat Urinary KIM-1 Rapid Test	25 strips
R-RENA-50	Rat Urinary KIM-1 Rapid Test	50 strips



**ARGUTUS MEDICAL**

An EKF Diagnostics Company

**Argutus Medical Ltd.**

**Unit 9 Trinity Technology & Enterprise Campus,  
Pearse Street, Dublin 2, Ireland**

**Tel: +353 1 670 8576**

**Fax: +353 1 670 8575**

[info@argutusmed.com](mailto:info@argutusmed.com)

<http://www.argutusmed.com>

Document code RAT-126-07  
12/2011